Stephen B. Shrewsbury - Sep 21, 2021 Form 4 Insider Report for IMPEL NEUROPHARMA INC (IMPL)

Role
Chief Medical Officer
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Stock symbol
IMPL
Transactions as of
Sep 21, 2021
Transactions value $
$199,720
Form type
4
Date filed
9/22/2021, 04:57 PM
Previous filing
Jul 26, 2021
Next filing
Jan 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMPL Common Stock Options Exercise $29.1K +14.8K $1.97 14.8K Sep 21, 2021 Direct
transaction IMPL Common Stock Options Exercise $11.4K +4.65K +31.46% $2.46 19.4K Sep 21, 2021 Direct
transaction IMPL Common Stock Options Exercise $159K +54K +277.68% $2.95 73.4K Sep 21, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Options Exercise $0 -14.8K -100% $0.00* 0 Sep 21, 2021 Common Stock 14.8K $1.97 Direct F1
transaction IMPL Stock Option (right to buy) Options Exercise $0 -4.65K -89.58% $0.00 541 Sep 21, 2021 Common Stock 4.65K $2.46 Direct F2
transaction IMPL Stock Option (right to buy) Options Exercise $0 -54K -64.58% $0.00 29.6K Sep 21, 2021 Common Stock 54K $2.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is 100% vested and exercisable.
F2 The option vested as to 25% of the total shares on February 13, 2019, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on February 13, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
F3 The option vested as to 25% of the total shares on February 8, 2020, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on February 8, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.